ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
RBMS1 Contributes to Early Arteriovenous Fistula Neointimal Remodeling Through Modulation of VSMC Phenotypic Responses.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Arteriovenous fistula (AVF) creation initiates stage-dependent remodeling of the venous outflow tract. Neointimal hyperplasia is a common component of this response, but its post-transcriptional regulation remains unclear. Here, analyses of human AVF datasets and tissue specimens characterized RNA-binding motif single-stranded interacting protein 1 (RBMS1) expression in postoperative AVFs, whereas a day-14 mouse AVF model and cultured vascular smooth muscle cells (VSMCs) were used to investigate its role in early neointimal remodeling. Smooth muscle-targeted RBMS1 overexpression aggravated neointimal formation, whereas conditional RBMS1 deletion attenuated it in murine AVFs. In cultured VSMCs, RBMS1 overexpression enhanced proliferation, migration, and the transition from contractile to synthetic marker expression, whereas RBMS1 silencing produced the opposite effects. Mechanistically, RBMS1 bound myelin protein zero-like 1 (MPZL1) mRNA and promoted exon 5 skipping, generating the MPZL1-Δ5 isoform. MPZL1-Δ5 overexpression reproduced selected RBMS1-associated VSMC responses and increased neointimal hyperplasia in vivo, including in RBMS1-deficient mice. MPZL1-Δ5 further interacted with GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) and enhanced protein kinase B (AKT) activation, whereas G3BP1 silencing attenuated RBMS1- or MPZL1-Δ5-induced VSMC responses. Together, these findings identify the RBMS1-MPZL1-Δ5-G3BP1-AKT pathway as an important VSMC-associated mechanism contributing to neointimal remodeling during the early postoperative phase of experimental AVFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.